|
Spring Bank Pharmaceuticals |
|
|
113 Cedar Street, Ste S-7
Milford, MA 01757 USA
phone:508-473-5993
fax:
|
|
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.springbankpharm.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| discovery and development of treatments for life threatening viral infections. |
|
| Management |
|
| |
|
|
| |
|
| Keywords |
| early stage, pharmaceutical, company, discovery, development, treatments, life threatening, viral infections, autoimmune diseases, cancer, nucleic, acid based, chemistry, small molecule discovery |
|
|
|
| Description |
|
Spring Bank Pharmaceuticals is an IND-stage drug discovery company. Based on our proprietary platform technology, we are developing a pipeline of products representing a new class of pharmaceuticals we call small molecule nucleic acid hybrids �SMNH� with a wide range of applications and multi-billion dollar market potential. These rationally designed molecules combine the target selectivity and specificity advantages of nucleic-acid-based therapeutics, like RNAi and antisense oligonucleotides, with the drug-like properties of classical pharmaceuticals, including oral delivery, good pharmacokinetics, low side effects and ease of manufacture. Our most advanced product is SB 9200, a potential breakthrough drug for Hepatitis B and C with both direct antiviral and immune stimulatory activities, for which we plan to begin Phase I trials in early 2011. Behind SB 9200 are drug discovery programs for COPD, other viral infections and cancer. Since our founding in 2002, we have built our technology platform and product pipeline using a capital-efficient semi-virtual business model, supported by more than $8M of non-dilutive NIH grants. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members